Background: Necrotizing enterocolitis (NEC) is an inflammatory bowel necrosis of premature infants. Based on our recent findings of increased Smad7 expression in surgically resected bowel affected by NEC, we hypothesized that NEC macrophages undergo inflammatory activation because increased Smad7 expression renders these cells resistant to normal, gut-specific, transforming growth factor (TGF)-β-mediated suppression of inflammatory pathways. Methods: We used surgically resected human NEC tissue, murine models of NEC-like injury, bone marrow-derived and intestinal macrophages, and RAW264.7 cells. Smad7 and IκB kinase-beta (IKK-β) were measured by quantitative PCR, western blots, and immunohistochemistry. Promoter activation was confirmed in luciferase reporter and chromatin immunoprecipitation assays. results: NEC macrophages showed increased Smad7 expression, particularly in areas with severe tissue damage and high bacterial load. Lipopolysaccharide-induced Smad7 expression suppressed TGF-β signaling and augmented nuclear factor-kappa B (NF-κB) activation and cytokine production in macrophages. Smad7-mediated NF-κB activation was likely mediated via increased expression of IKK-β, which, further increased Smad7 expression in a feed-forward loop. We show that Smad7 induced IKK-β expression through direct binding to the IKK-β promoter and its transcriptional activation. conclusion: Smad7 expression in NEC macrophages interrupts TGF-β signaling and promotes NF-κB-mediated inflammatory signaling in these cells through increased expression of IKK-β. n ecrotizing enterocolitis (NEC) continues to be a leading cause of death among neonates born before 32 wks of gestation (1). The etiology of NEC is complex and not well understood, although current evidence suggests that NEC may occur in the preterm intestine when an altered/disrupted epithelial barrier allows bacterial translocation from the lumen into the bowel wall, where these bacteria and their products trigger an exaggerated and damaging inflammatory reaction (2).
n ecrotizing enterocolitis (NEC) continues to be a leading cause of death among neonates born before 32 wks of gestation (1) . The etiology of NEC is complex and not well understood, although current evidence suggests that NEC may occur in the preterm intestine when an altered/disrupted epithelial barrier allows bacterial translocation from the lumen into the bowel wall, where these bacteria and their products trigger an exaggerated and damaging inflammatory reaction (2) .
The cellular inflammatory response in NEC lesions is marked by macrophage-rich infiltrates (3) (4) (5) . In both the inflamed and noninflamed intestinal mucosa, macrophage populations are maintained through recruitment of circulating monocytes to the lamina propria (6, 7) . In the healthy mucosa, newly recruited macrophage precursors undergo inflammatory downregulation under the influence of transforming growth factor-beta (TGF-β) present in the local extracellular matrix. Intestinal macrophages display avid phagocytic and bacteriocidal activity, but do not produce cytokines upon exposure to bacterial products (8) . This "inflammatory anergy" of macrophages in the uninflamed mucosa contrasts with macrophages in NEC lesions, which express a variety of cytokines and other inflammatory mediators (4) . We recently showed that surgically resected bowel with NEC shows increased expression of Smad7, which is a negative regulator of TGF-β signaling (9) . Based on this information, we now hypothesized that the increased Smad7 expression seen in NEC promotes inflammatory activation of NEC macrophages by rendering these cells resistant to normal TGF-β-mediated suppression of inflammatory pathways. In the following sections, we present data from human intestinal tissue samples of NEC, our previously described neonatal murine model of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-mediated intestinal injury, which shows mucosal inflammation similar to NEC (4), and from native and genetically modified murine macrophages.
Based on the observations in surgically resected human NEC tissue, we postulated that bacterial products such as lipopolysaccharide (LPS) drive Smad7 expression during NEC. Consistent with this hypothesis, LPS treatment of RAW264.7 murine macrophages induced Smad7 expression in these cells (Figure 2a,b) . Similar results were obtained when RAW264.7 cells were stimulated with flagellin (Salmonella typhimurium; 
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Articles not depicted). We also detected increased Smad7 expression in intestinal tissue from pups with TNBS-induced enterocolitis (Figure 2c,d ) and in macrophages isolated from affected bowel by immunomagnetic separation (Figure 2e ). Smad7 expression in gut macrophages in TNBS enterocolitis was further confirmed by immunohistochemistry (Figure 2f ). TNBSmediated intestinal injury occurs only in the presence of gut microbial flora and not in germ-free mice (4), and therefore, in conjunction with those from human NEC specimens and the in-vitro models, these findings were interpreted as evidence that bacterial products induce Smad7 expression in neonatal gut macrophages during NEC. We further confirmed these findings in another murine model where NEC-like injury was induced in formula-fed mice exposed to hypoxia and hypothermia. NEC-like injury increased Smad7 expression by 2.8 ± 0.3 folds over control (P < 0.05; not depicted).
Developmental Differences in Macrophage Smad7 Expression
We have previously shown that the preterm intestine is developmentally deficient in the Ski-like protein, which is 
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Intestinal injury a physiological repressor of the Smad7 promoter (9, 10) . Therefore, we now asked whether these developmental differences extend to hematopoietic cells such as macrophages and compared Smad7 expression in BMDMs from 10-d-old mouse pups and adult animals. Unlike macrophages from adult mice, neonatal macrophages were able to upregulate Smad7 expression upon exposure to LPS (Figure 3a) . There was no difference in constitutive Smad7 expression (not depicted). Consistent with our earlier findings, neonatal macrophages expressed less Ski-like mRNA than macrophages from adult mice (Figure 3b) .
LPS-Mediated Suppression of TGF-β Signaling in Macrophages is Mediated via Smad7
In the healthy intestinal mucosa, macrophages undergo inflammatory downregulation under the influence of TGF-β isoforms TGF-μ 2 and TGF-β1 (8, 11) . We asked whether bacterial products present in NEC lesions could interrupt this normal, TGF-β-mediated non-inflammatory differentiation of gut macrophages. Consistent with this hypothesis, LPS treatment of RAW264.7 cells blocked TGF-β 2 -induced Smad2 phosphorylation (Figure 4a ). We next used Smad7 knockdown to investigate whether these LPS effects are indeed mediated via Smad7. In these experiments, we used the SRE-reporter RAW264.7 cells, which express a TGF-β-responsive luciferase reporter construct (12) and performed transient transfection with a Smad7 shRNA plasmid to achieve Smad7 knockdown in these cells. After overnight treatment with LPS, these cells were stimulated with TGF-β2 × 1h and the relative strength of the TGF-β signal was measured as luciferase activity. Smad7 knockdown reversed LPS-mediated suppression of TGF-β signaling in macrophages (Figure 4b) . Finally, we investigated the contribution of Smad7 to the inflammatory activation of macrophages by comparing LPS-induced cytokine expression in control and Smad7-overexpressing RAW264.7 cells. As shown in Figure 4c , cells overexpressing Smad7 produced more interleukin (IL)-1β, IL-6, tumor necrosis factor, and granulocyte macrophage-colony stimulating factor than control.
Smad7 Augments LPS-Induced NF-κB Activation in Macrophages by Inducing IKK-β Expression in These Cells
Because TGF-β 2 normally suppresses nuclear factor-kappa B (NF-κB)-mediated inflammatory signaling in gut macrophages (11), we next asked whether increased Smad7 expression during NEC would augment NF-κB activation in these cells. To test this hypothesis, we used the NF-κB/SEAP reporter RAW264.7 cells, which express secreted embryonic alkaline phosphatase (SEAP) activity upon NF-κB activation. These cells were transiently transfected to overexpress Smad7. Compared with control, Smad7-overexpressing macrophages showed a significant increase in LPS-induced NF-κB activation (Figure 5a) .
To identify the specific signaling mediator(s) through which Smad7 augments LPS-induced NF-κB activation, we used reverse transcriptase-quantitative PCR to compare control and Smad7-overexpressing RAW264.7 cells for mRNA expression of key NF-κB pathway genes. Out of 14 genes included in this panel, IKK-β was the only one to show significant induction in Smad7-overexpressing cells (Figure 5b) . We also examined a few, well-established mediators in the toll-like receptor-4-activated signaling pathway but did not detect increased expression for genes included in this panel (Figure 5c ). Smad7-overexpressing cells showed decreased expression of TIRdomain-containing adapter-inducing interferon-β, which is a key adaptor involved in toll-like receptor-associated delayed signaling cascades. Data from TIR-domain-containing adapterinducing interferon-β knockout mice (13) suggest that the loss of TIR-domain-containing adapter-inducing interferon-β expression alone cannot explain increased tumor necrosis factor, IL-6, and IL-1β production by Smad7-overexpressing macrophages, and therefore, we decided to focus on IKK-β as our mediator of interest in this study.
We next confirmed increased IKK-β expression in Smad7-overexpressing RAW264.7 cells at the protein level (Figure 5d) . In support of our findings, we detected increased IKK-β expression in intestinal tissue from pups with TNBS-induced Articles enterocolitis and in macrophages isolated from affected bowel by immunomagnetic separation (Figure 5e ). To elucidate the mechanisms by which Smad7 overexpression increased IKK-β expression, we cotransfected RAW264.7 cells to overexpress Smad7 and also express a luciferase reporter driven by the IKK-β promoter. Compared with control, Smad7-overexpressing cells showed significantly greater activation of the IKK-β promoter (Figure 5f ). Finally, to determine whether Smad7 effects on IKK-β expression were direct and specific, or were secondary to interrupted TGF-β signaling as noted in Figure 4a ,b (which would presumably increase NK-κB-mediated transcription), we investigated whether TGF-β played a role in IKK-β gene expression. Treatment of RAW264.7 cells with rTGF-β 2 did not suppress IKK-β expression to levels below the constitutive state. In LPS-stimulated cells, rTGF-β 2 showed a significant, but partial suppression (Figure 5g) . These findings did not convincingly exclude direct effects of Smad7 on IKK-β transcription, and therefore, we next investigated whether Smad7 could directly activate the IKK-β gene promoter. These experiments were also warranted 
Smad7 Induces IKK-β Expression in Macrophages by Directly Activating its Promoter
To investigate whether the IKK-β promoter displays Smadbinding element(s), we first aligned human and murine IKK-β promoter sequences in silico using the application MULAN (14) to identify conserved regions, and then used (mean values ± SEM) shows luciferase activity in control and Smad7-overexpressing RAW264.7 cells, transfected with a luciferase reporter carrying the IKK-β promoter. Data were normalized for total protein in the cell lysates; (g) rTGF-β 2 suppression of LPS-induced IKK-β expression is not complete. Bar diagrams (mean values ± SEM) shows fold change in IKK-β mRNA in RAW264.7 cells in media alone, treated with LPS (0.5 μg/ml × 1 h and then cultured overnight), rTGF-β 2 (500 ng/ml, overnight), or LPS stimulation × 1 h followed by rTGF-β 2 overnight. *P < 0.05, **P<0.01 vs. control; † P < 0.05 vs. LPS-treated control cells. Two-group comparisons performed by the Mann-Whitney U-test; Kruskal-Wallis H test (with pairwise comparisons) used for multiple groups. IKK-β, IκB kinase-beta; LPS, lipopolysaccharide; NF-κB, nuclear factor-kappa B; SEAP, secreted embryonic alkaline phosphatase; TLR, toll-like receptor; TNBS, 2, 4, 6-trinitrobenzene sulfonic acid. (Figure 6a) . Using anti-Smad7 antibody and specific primers designed to detect a 150-bp amplicon that included these two Smad-binding elements (Table 1) in a ChIP assay, we demonstrated Smad7 binding to the IKK-β promoter in RAW264.7 cells (Figure 6b) . To confirm these findings in vivo, we repeated the ChIP on intestinal tissue with TNBS-induced enterocolitis and showed Smad7 binding to the IKK-β promoter in control intestine and further enrichment of Smad7 in TNBS-induced NEC-like injury (Figure 6c) . To determine whether Smad7 binding to the IKK-β promoter actually resulted in transcriptional activation, we sought epigenetic marker(s) of euchromatin on the IKK-β nucleosome. Because Smad7 augments LPS-induced NF-κB activation in macrophages, we measured the acetylation of Lys12 residue on histone H4 (H4K12; an epigenetic modification characteristic of LPS-induced transcriptional activation) on the IKK-β nucleosome (15) . We repeated the ChIP assay using antiacetyl-H4K12 and the primers for the IKK-β promoter sequence described above, which confirmed that Smad7 promoted the development of acetyl-H4K12 marks on the IKK-β nucleosome (Figure 6d) . These findings were then confirmed in vivo by repeating the ChIP assay on intestine from pups with TNBS enterocolitis (Figure 6e) .
IKK-β Promotes Smad7 Expression in Macrophages and Forms a Positive Feedback Loop of Inflammatory Activation
In chondrocytes, NF-κB activation can induce Smad7 expression (16) . Therefore, we asked if increased IKK-β expression in inflammatory macrophages could promote Smad7 expression and thereby complete a feed-forward activation loop. Consistent with this hypothesis, transient transfection of RAW264.7 cells to overexpress IKK-β increased Smad7 at both mRNA and protein levels (Figure 7a,b) .
DISCUSSION
We present a detailed investigation into the role of Smad7 in inflammatory activation of NEC macrophages. We show that bacterial products induce Smad7 expression in neonatal macrophages, which can interrupt TGF-β-mediated inflammatory downregulation of macrophages that normally occurs following recruitment to the noninflamed mucosa. Smad7 sensitizes macrophages to bacterial products and promotes NF-κB activation and cytokine production in these cells. To Articles our knowledge, this is the first study to show that Smad7 can induce IKK-β expression in macrophages through direct binding and transcriptional activation of the IKK-β promoter. We also show that increased IKK-β expression can promote Smad7 expression, thereby setting up a feed-forward loop in the inflammatory activation of macrophages (Figure 7c) . In this study, we used our previously described model of TNBS-induced murine neonatal acute necrotizing enterocolitis to study NEC (4). This model was originally conceived because (i) the incidence of NEC peaks at 32 wks corrected gestational age (17) ; and (ii) clinical antecedents of NEC are diverse and often difficult to connect by a unifying mechanism of injury. Emphasizing the developmental predilection (over specific insults) in the pathogenesis of NEC, we postulated that the pathoanatomy of NEC represents a generic tissue injury response of the developing intestine that could be evoked nonspecifically by a variety of antecedent insults (4) . In this context, we used TNBS as a nonspecific, but predictable, immunological insult to cause bowel injury in neonatal mice. The mechanisms by which TNBS induces inflammation in the neonatal intestine are not clear and likely differ from those postulated in adult animals. In adult mice, TNBS is believed to activate Th1-Th17 lymphocytes in the mucosa (18) , whereas TNBS enterocolitis in pups is marked by macrophage-rich infiltrates with very few lymphocytes (4). Also, TNBS causes severe mucosal injury in C57BL/6 pups, even though adult animals of this strain are relatively resistant to TNBS (4). TNBS does not cause injury in germ-free mice, indicating that the mucosal damage requires the presence of bacteria and is not caused by direct chemical/ corrosive action. As a model of NEC, TNBS-induced neonatal enterocolitis offers some important advantages: (i) the cellular inflammatory response resembles surgically resected tissue samples of NEC (4); (ii) similar to NEC (19) , TNBS enterocolitis requires the presence of gut microflora (4); (iii) unlike the hypothermia-hypoxia model where individual animals develop bowel injury at different times during the NEC protocol, the temporal evolution of bowel injury can be accurately mapped from the time of TNBS administration; (iv) administration of weight-normalized doses of TNBS in mouse pups and adults can facilitate the study of developmental aspects of NEC. Infectious agents such as Enterobacter sakazakii (20) can also allow age-based comparisons, but the dose of the inciting agent (luminal Enterobacter populations) is difficult to control due to ongoing bacterial proliferation; (v) unlike models where bowel injury is induced by platelet-activating factor or splanchnic ischemia-reperfusion and the animals need to be killed within a few hours (21, 22) , mice subjected to TNBS enterocolitis can be observed for several days to study sequential inflammatory changes; (vi) because all pups are affected predictably, fewer animals are needed (vs. the hypoxia-hypothermia model where only 40-70% animals develop injury); and (vii) the use of 10-d-old pups allows time to test prophylactic interventions; it was convenient that the rodent intestine at birth resembles the preterm human intestine and takes 3 wks to undergo structural and functional maturation seen in the term human neonate (23, 24) .
Unlike macrophages from adult mice, neonatal macrophages were able to upregulate Smad7 expression upon exposure to LPS. These data are consistent with our earlier report that the gut epithelium in the premature intestine expresses Smad7 at high levels because of the developmental deficiency of the skilike protein, which normally binds the Smad7 promoter and maintains it in state of repression (10) . Ski-like protein is generally expressed at very low levels in the fetus, except for specific developmental epochs (25) .
Smad7 is an important negative regulator of TGF-β signaling in the gastrointestinal tract (26) . We have previously demonstrated high Smad7 expression both in the uninflamed preterm intestine and during NEC, where it blocks normal autocrine induction of TGF-β 2 in epithelial cells (9) . Smad7 can suppress TGF-β signaling by competing with activating Smads, interfering with TGF-β receptor function and increasing its degradation, or through epigenetic mechanisms by interacting with histone deacetylases (14, 27, 28) . In this study, we show that Smad7 can also promote inflammation through direct activation of the IKK-β promoter in macrophages. IKK-β is an essential catalytic subunit of the IKK complex, which includes another catalytic subunit, IKK-α, and a regulatory subunit, IKK-γ. During inflammation, cytokines and bacterial products promote phosphorylation of IKK-β, which in turn, activates the IKK complex. Activated IKK phosphorylates the IκBs, triggering their degradation and thereby releasing the NF-κB dimers for nuclear translocation. In our study, Smad7 activation of the IKK-β promoter was associated with increased H4K12 acetylation, which is an epigenetic marker of euchromatin (29) , on the IKK-β nucleosome. H4K12 acetylation presumably neutralizes its electrical charge, leading to structural changes that promote DNA accessibility and interactions with the H2A-H2B dimer in neighboring histones (30) . In addition to Smad7 effects on IKK-β expression, we have also shown that increased IKK-β forms a feed-forward activation loop and upregulates Smad7 expression. Although we did not investigate the mechanisms for IKK-β-mediated Smad7 expression in macrophages, our findings are consistent with existing data in other cell lineages where IKK-β mediates LPS-induced phosphorylation of Rel A/ p65 (31) , which, in turn, can trigger Smad7 expression (16) .
In conclusion, we have shown that Smad7 promotes the inflammatory activation of NEC macrophages and is a potential therapeutic target. We acknowledge that rodent models, important for proof-of-concept studies, may not always simulate pathological changes in a natural disease process. There is a need for further corroboration of these findings in clinical studies, which can provide complementary information on the role(s) of comorbidities and the clinical course, feeding experience, and the microbial flora.
METHODS

Human NEC and Controls
Deidentified formalin-fixed paraffin-embedded archived human intestinal tissues were used at University of Illinois at Chicago. The Institutional Review Board at the University of Illinois at Chicago deemed this study as not involving human subjects. Sections of NEC (n = 8) were compared with healthy tissue margins resected for
